- Home
- TLSI vs CERS Comparison
TLSI vs CERS Comparison
Compare TLSI & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSI | CERS |
|---|---|---|
| Founded | 2010 | 1991 |
| Country | United States | United States |
| Employees | 110 | N/A |
| Industry | Medical Specialities | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.1M | 276.0M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | TLSI | CERS |
|---|---|---|
| Price | $4.16 | $1.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 198.2K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | $41.93 | $20.00 |
| Revenue Next Year | $41.75 | $9.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $3.42 | $1.12 |
| 52 Week High | $7.95 | $2.96 |
Technical Indicators
Market Signals| Indicator | TLSI | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 35.61 | 32.71 |
| Support Level | $3.61 | $1.27 |
| Resistance Level | $5.51 | $2.26 |
| Average True Range (ATR) | 0.39 | 0.17 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 7.22 | 5.24 |
Price Performance
Historical ComparisonAbout TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.